Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
In a report published in the British Journal of Dermatology, researchers investigated further into the Vitiligo Noticeability Scale (VNS) by comparing results from the patient-reported and invesitgator-assesed studies. The VNS scale assesses cosmetic acceptability of repigmentation of individual lesions of vitiligo.
Data was collected from patients with vitiligo participating in a phototherapy trial to assess the noticeability of a single patch of vitiligo after nine months of treatment, then compared it with a baseline photo and score improvement using the noticeability scale. Researchers compared the score with the patient-reported global treatment success score for validation.
To further confirm the results, three other individuals with vitiligo rated the before and after images of the patients using the same scales. Three clinicians also rated the images for global treatment success and percentage repigmentation. The VNS showed good construct validity and the results were the same in all ages and skin types.
According to the report, these improved repigmentation outcomes are important to vitiligo patients as any improvement indicates the condition is no longer worsening.
Data included that 14.6% of subjects in the present study valued a VNS score of only 2 corresponding to no change innoticeability. According to researchers, the improvement in noticeability in this study depends on the eye of the beholder, as the raters with vitiligo and clinicians did not share this enthusiasm with the subject.
Researchers also suggested that results of the study will be beneficial to other researchers planning trials for new treatments. As with previous studies, a level of 75% or greater repigmentation of a target lesion was confirmed to be significant in this study.
As the VNS is used more frequently, it will be easier to compare treatments and we will learn even more about this PROM as it is used in wider, more diverse groups in the future, the report said.
Lastly, it was suggested research should be performed to develop PROMs that are static and measure improvement in all vitiligo lesions in a single patient.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More
High Sodium Intake Associated to Increased Risk of Severe Atopic Dermatitis
June 20th 2024Researchers who conducted the study, of the Universities of California in San Francisco and Berkley, suggest that cutting down on sodium could be a more cost-effective and low-risk way to help manage AD.
Read More
Highly Contagious and Hard-to-Treat Fungal Skin Infections Are Emerging, Experts Warn
June 6th 2024Experts are urging healthcare providers to be aware of these two new forms of ringworm or jock itch, known as Trichophyton mentagrophytes type VII (TMVII) and Trichophyton indotineae or T. indotineae.
Read More